• Anp32e Drives Renal Fibrosis via TGF-β1/Smad3 Pathway Activa

  2026-08-04

  This study demonstrates that Anp32e promotes renal interstitial fibrosis by upregulating fibrosis-related proteins through activation of the TGF-β1/Smad3 signaling pathway. Crucially, pharmacological inhibition of ALK5 with SB 431542 reverses these pro-fibrotic effects in vitro, providing mechanistic insight and suggesting new targets for therapeutic intervention in chronic kidney disease.

• CBD Attenuates Orofacial Pain and Affective Deficits via Mul

  2026-08-04

  This study demonstrates that cannabidiol (CBD) suppresses both sensory and affective components of orofacial inflammatory pain in mice. Mechanistic insights reveal coordinated modulation of peripheral and central cannabinoid and serotonergic pathways, supporting CBD’s translational potential for multidimensional pain management.

• Inflammatory Mechanisms and Biomarker Strategies in Ischemic

  2026-08-03

  This review systematically synthesizes current knowledge on the inflammatory response in ischemic stroke, emphasizing the dual role of neuroinflammation in both injury progression and repair. It highlights advances in biomarker-based diagnosis and treatment, presenting a unified framework for translational research and clinical application.

• YC-1: sGC Activator & HIF-1α Inhibitor for Tumor Research

  2026-08-03

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a highly pure small molecule sGC activator and HIF-1α inhibitor. It is widely used to investigate tumor angiogenesis, hypoxia signaling, and apoptosis in cancer research. APExBIO supplies YC-1 with verified purity and solubility, supporting advanced experimental workflows.

• Cholesterol (SKU B1702): Optimizing Membrane Assays in the L

  2026-08-02

  This article addresses common challenges in cell viability and membrane fluidity assays by exploring the scientific and practical merits of Cholesterol (SKU B1702) from APExBIO. Scenario-driven Q&A blocks guide researchers on reproducibility, solubility, and vendor reliability, supporting data-backed decision making for advanced lipid metabolism research.

• SCH772984: Next-Gen ERK1/2 Inhibitor for Tumor Pathway Disse

  2026-08-01

  Explore how SCH772984, a selective ERK1/2 inhibitor, enables precise dissection of MAPK/ERK pathway signaling in complex tumor models. This article goes beyond protocols to analyze emerging mechanistic insights and practical assay implications, offering a new perspective for advanced oncology research.

• ERK5 and ERK1/2 Roles in Vitamin D-Induced AML Differentiati

  2026-07-31

  This study reveals the distinct and critical involvement of the ERK5/MAPK pathway in the terminal differentiation of myeloid leukemia cells driven by 1α,25-(OH)2 vitamin D3. By dissecting the effects of selective pathway inhibition, the research clarifies cell cycle regulation and suggests new combinatorial strategies for acute myeloid leukemia therapy.

• Isorhamnetin: Advancing Oocyte Maturation via PI3K/Akt Pathw

  2026-07-31

  Isorhamnetin, a potent flavonoid modulator, elevates in vitro oocyte maturation by regulating PI3K/Akt and MAPK signaling, providing a robust edge in oxidative stress and apoptosis research. This guide translates bench breakthroughs into actionable protocol upgrades and troubleshooting strategies for reproductive and cellular stress assays.

• AI-10-49 and the N-MYC/eIF4G1 Axis: Innovating AML Research

  2026-07-30

  This article explores the mechanistic and translational impact of AI-10-49, a selective CBFβ-SMMHC inhibitor, on acute myeloid leukemia—spotlighting the pivotal N-MYC/eIF4G1 axis in inv(16) AML. It provides strategic guidance for researchers, integrates leading evidence, and frames AI-10-49 as a next-generation research tool for unlocking new therapeutic avenues.

• Jasplakinolide in Chemical Genetics: Redefining Actin Assays

  2026-07-30

  Explore how Jasplakinolide, a premier actin polymerization inducer, enables advanced chemical genetics and cytoskeletal dynamics studies. This article uniquely bridges actin research with actionable assay design, grounded in leading-edge scientific evidence.

• AZD1390: Ultra-Potent ATM Kinase Inhibitor for DNA Repair St

  2026-07-29

  AZD1390 is a highly selective ATM kinase inhibitor that enables precise interrogation of DNA double-strand break repair and cell cycle regulation in cancer research. It delivers sub-nanomolar potency, especially in radiosensitizing glioma and lung cancer cells. Validated in cellular and in vivo models, AZD1390 advances mechanistic studies and translational workflows.

• 1,2-Dioleoyl-3-trimethylammonium-propane Chloride in Precisi

  2026-07-29

  DOTAP empowers high-efficiency nucleic acid delivery across gene expression, functional genomics, and immunometabolic modulation workflows. This article dissects practical protocol enhancements and troubleshooting insights, spotlighting how innovations from metabolic nanodelivery research elevate applied gene modulation.

• SCH772984: Precision ERK1/2 Inhibition for Tumor Radiosensit

  2026-07-28

  Explore how SCH772984, a selective ERK1/2 inhibitor, advances MAPK/ERK pathway research and tumor radiosensitivity studies. This article offers a unique, in-depth analysis of its mechanistic role, with insights beyond current literature.

• SCH772984: ERK1/2 Inhibitor Protocols for Tumor Radiosensiti

  2026-07-28

  SCH772984 offers precise MAPK/ERK pathway inhibition, making it a cornerstone for dissecting radioresistance mechanisms in mutant-driven cancers. This guide delivers actionable experimental protocols, troubleshooting insights, and translational perspectives for integrating SCH772984 into advanced cell and xenograft models.

• Sustained VX-770 Potentiation of CFTR in Primary Airway Epit

  2026-07-27

  This study rigorously demonstrates that even brief, low-concentration exposures to VX-770 (ivacaftor) can produce a persistent potentiation of CFTR channel activity in human airway epithelial cultures. The findings provide new insights into the pharmacodynamics of CFTR modulators and have direct implications for both experimental designs and clinical management of cystic fibrosis.

8608 records 3/574 page Previous Next 12345 下5页 Last page